眼科新进展2017，Vol.37Issue(4)：341-343,3.DOI:10.13389/j.cnki.rao.2017.0086
半剂量维替泊芬与半能量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变
Half-dose verteporfin and half-fluence photodynamic therapy for chronic central serous chorioretinopathy
摘要
Abstract
Objective To compare the efficacy and safety of half-dose verteporfin and half-fluence photodynamic therapy in chronic central serous chorioretinopathy (CSC).Methods The medical records of 42 patients (42 eyes) with chronic CSC were retrospectively reviewed.According to the difference of drug dose and laser parameters in the course of PDT,the patients were divided into two groups:half-dose group and half-fluence group.Half-dose group:22 patients (22 eyes) received half-dose verteporfin(3 mg· m-2)and standard PDT(83 s,50 J · cm-2).Half-fluence group:20 patients (20 eyes) received full-dose verteporfin (6 mg · m-2) and half-fluence PDT (42 s,25 J · cm-2).Patients were followed up at 1 month,3 months,6 months after PDT.The outcome measures was the proportion of eyes with complete resolution of subretinal fluid(SRF),the changes in best corrected visual acuity (BCVA) and central retinal thickness(CMT).Results At 6 months after PDT,22 eyes(100％) that received half-dose PDT showed complete resolution of SRF,19 eyes(95％)that received half-fulence PDT showed complete resolution of SRF.There was no statistical difference between two groups (P ＞ 0.05).At 6 months after PDT,the mean BCVA improved 7.2 letters in half-dose group and 6.7 letters in half-fluence group.There was no statistical difference compared with the improvement of BCVA between two groups(P ＞ 0.05).In half-dose group,mean baseline central retinal thickness was (351 ± 90) μm,which was decreased to (178 ±55) μm after 6 months,respectively (P ＜ 0.05).In half-fluence group,mean baseline central retinal thickness was (322 ± 96) μm,which was decreased to (181 ± 47) μm after 6 months,respectively (P ＜ 0.05).None of the patients developed retinal pigment epithelium atrophy and CNV.Conclusion Half-dose verteporfm PDT and half-fluence PDT are effective and safe in the treatment of chronic CSC.关键词
光动力学疗法/慢性中心性浆液性脉络膜视网膜病变/维替泊芬Key words
photodynamic therapy/chronic central serous chorioretinopathy/verteporfin分类
医药卫生引用本文复制引用
马为梅,雷晓琴,田芳,周荣乐..半剂量维替泊芬与半能量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2017,37(4):341-343,3.基金项目
陕西省科技厅社会发展科技攻关项目(编号:2015SF232、2015SF085、2015SF106) （编号:2015SF232、2015SF085、2015SF106）
西安市科技局社会发展引导计划-医学研究项目[编号:SF1513(3)]Science and Technology Research Project of Shaanxi Provincial Science and Technology Department (No:2015SF232,2015SF085,2015SF106) （3）
Xi'an Municipal Science and Technology Bureau social development guide plan-medical research project[No:SF1513 (3)] （3）
